← Back

Guangdong Green Precision Components Co. Ltd.

9.64-38.3%1Y · CNY

Guangdong Green Precision Components Co., Ltd. is engaged in the research, development, design, production, and sale of precision structural components and molds for intelligent terminals. Its products include die-cast insert injection molding middle frames, metal middle frames, plastic battery covers with integrated LAP antennas, internal LDS antenna brackets and buttons, as well as components for antenna, electromagnetic shielding, acoustic cavity, heat dissipation, waterproof, and dustproof functions. The company also supplies front and back shells, windows, wrist straps, and molds for applications such as plastic molding, insert injection molding, IMD, ICM, secondary injection molding, and soft rubber composite molding. It serves smart speakers, doorbells, cameras, phones, bracelets, watches, smart home appliances, e-books, wearable devices, cleaning robots, unmanned aerial vehicles, AI glasses, tablet computers, and electronic cigarettes, and also offers GCPC masks. Founded in 2002, the company is based in Huizhou, China.

Price · split & dividend adjusted
News & notes moving 300968.CS
ChinaVietnam
300968.CS▼

Gelin Precision posts first-half loss of 75.45 million yuan, swinging to a loss from profit a year earlier

Gelin Precision released its 2026 interim report on August 27. First-half operating revenue was 702 million yuan, up 30.0 percent year on year, but the company posted a loss of 75.45 million yuan, a year-on-year decline of 12,238.6 percent, swinging from profit to loss. Net profit attributable to the parent after deducting non-recurring items was a loss of 76.05 million yuan, with the loss widening further from the same period last year. Net operating cash flow was negative 7.74 million yuan, down 109.8 percent year on year. Earnings per share were negative 0.1825 yuan. In the second quarter, operating revenue was 398 million yuan, up 19.8 percent year on year, while net profit attributable to the parent was a loss of 30.39 million yuan, down 356.2 percent year on year. As of the end of the second quarter, total assets were 2.175 billion yuan, down 2.0 percent from the end of the previous year, and net assets attributable to the parent were 1.751 billion yuan, down 4.5 percent from the end of the previous year. The company said that although operating revenue grew, the weakening of the US dollar against the yuan and intensifying competition in external markets put pressure on product selling prices, resulting in a net loss. To cope with macroeconomic volatility, the first-phase plant at its Vietnam production base has been topped out and is expected to strengthen core competitiveness.
300968.CS · Capital · Negative First-half loss of 75.45 million yuan, swinging from profit, with revenue up but margins pressured.
Read original ↗
财中社·39dRead more →
Brain-Computer Interface▲

Harbin Pharmaceutical hits 5th consecutive daily limit, leading innovative drug rally; on-device AI and brain engineering sectors active

In early trading on July 16, Harbin Pharmaceutical hit its fifth consecutive daily limit, making it the stock with the longest winning streak among those still on a streak that day. The innovative drug theme remained strong, with Wanbang Pharmaceutical and Puruis rising over 10 percent. The on-device AI concept heated up, as Green Precision sealed a 20 percent daily limit, and Daoming Optics and Furong Technology also hit their daily limits. On the news front, seven on-device generative AI services completed regulatory filings, and the 2026 World Artificial Intelligence Conference is set to take place in Shanghai. The brain engineering sector saw a sudden surge during the session, with Chuangxin Medical hitting its daily limit in a straight line, and Saili Medical and Aipeng Medical following higher. The world's first implantable brain-computer interface system, NEO, saw its first prescription issued in Shanghai after receiving market approval. Total market turnover exceeded 1.4 trillion yuan, shrinking by 236.7 billion yuan compared with the same period last session, with over 3,200 stocks advancing.
About megatrends
Brain-Computer Interface › Invasive BCI Systems ▲Regulation
Artificial Intelligence › Edge & On-device AI Silicon Regulation
600664.CG · Demand · Positive Harbin Pharmaceutical hit its fifth consecutive daily limit, leading the innovative drug rally.
002173.CS · Technology · Positive Chuangxin Medical hit its daily limit after the world's first implantable BCI system NEO received market approval.
002632.CS · Demand · Positive Daoming Optics hit its daily limit as the on-device AI concept heated up.
300968.CS · Demand · Positive On-device AI concept heats up; Green Precision sealed a 20% daily limit as part of the rally.
603327.CG · Demand · Positive Furong Technology hit its daily limit as the on-device AI concept heated up.
603716.CG · Demand · Positive Wuhan Thalys Med Tech (Puruis) rose over 10% as part of the innovative drug theme.
Read original ↗
上海证券报·81dRead more →